| Welcome |
| About Foamix |
| Technologies |
| Products |
| Strategy |
| Contact |
| News |
| Useful Links |
 |
||
|
12/09/2011
Foamix to Present at the UBS 2011 Global Life Sciences Conference, Including an Update on its First-in-Class Topical Minocycline Foam , Now in Phase II for Acne, Rosacea and Skin Infections
Rehovot (Israel), September 12, 2011 Foamix Ltd., will present at the UBS 2011 Global Life Sciences Conference, which will be held in New York City on September 19-21, 2011. Dov Tamarkin, Ph.D., Foamix's CEO, will speak on Tuesday, September 20, 2011 at 10:00 AM in Ballroom V. He will provide an overview of the Company, its innovative technologies and an update on its drug development pipeline, which includes the first-in-class Topical Minocycline Foam, as well as other proprietary products. Foamix’s is currently conducting Phase II clinical trials with Topical Minocycline Foam for Impetigo and Rosacea, and is currently commencing an additional Phase II study in patients with moderate to severe Acne. Topical Minocycline is also available as an OilGel™, which Foamix plans to develop for a number of ophthalmic indications. In addition Dr. Tamarkin will discuss the Company’s strategic partnerships with pharmaceutical companies. About Minocycline Foam: Minocycline, which is currently available only in oral tablets and capsules, is primarily used to treat acne, rosacea and skin infections. In a recent survey among American dermatologists, 95% indicated that they prescribe oral Minocycline for moderate and severe Acne and Rosacea; and most of them (87%) expressed their concerns about side effects, which include upset stomach, diarrhea, dizziness, unsteadiness, drowsiness, mouth sores, headache and vomiting. Foamix’s first-in-class topical Minocycline Foam is currently being studied in two Phase II clinical trials in Rosacea and Impetigo. Foam is preferred by users for topical treatment, due to its ease in spreading and quick absorption. The current sales of oral minocycline in the U.S. exceed $ 1.0 billion. About Foamix: Foamix Ltd. is a clinical-stage, privately held specialty pharma company, focused on the development of proprietary topical foam and OilGel™ products for prescription, OTC and cosmetic applications. Foamix creates advanced products with improved convenience, higher compliance and better efficacy, which are backed by an extensive patent portfolio. The company’s development capabilities range from initial development of the formulations to scale-up, GMP manufacturing, preclinical and clinical studies. Foamix partners with leading pharmaceutical companies, including Galderma, Intendis (Bayer’s dermatology company), Dr. Reddy's and Ferndale Laboratories. Foamix has a strong in-house pipeline of dermatological and gynecological drugs. The Company’s lead product, Topical Minocycline, is currently in Phase II clinical studies. To date, Foamix has 9 issued patents in the United States, covering its foam and OilGel™ technology platforms. The company has an additional 150 applications and patents worldwide, of which more than 60 applications are filed in the U.S. For additional information please see www.foamix.co.il
Contact: |